The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The ...

Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...

We recently compiled a list of the 8 Hot Growth Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

Boston Scientific Corporation (NYSE ... than BSX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

the estimate revisions trend for Boston Scientific: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report ...

On Friday, Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $83.62 which represents a decrease of $-0.40 or -0.48% from the prior close of $84.02. The stock opened at $84.33 ...